Long-term results of a phase II trial with frontline concurrent chemoradiotherapy followed by consolidation chemotherapy for localized nasal natural killer/T-cell lymphoma

Hui Jen Tsai, Sheng Fung Lin, Chu Chih Chen, Tsai Yun Chen, Wu Chou Su, Wen Li Hwang, Jin Ching Lin, Tzeon Jye Chiou, Weio Yau Kao, Chang Fang Chiu, Yi Fang Chang, Jeffrey S. Chang, Ming Chih Chang, Ih Jen Su

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Purpose: A phase II trial was conducted to evaluate the therapeutic efficacy and safety profiles of frontline concurrent chemoradiotherapy (CCRT) plus consolidation chemotherapy for patients with stage I/II nasal natural killer/T-cell lymphoma (NKTCL). Patients and methods: Patients with newly diagnosed, measurable stage I/II nasal NKTCL were eligible. The CCRT included two cycles of the DEP regimen (dexamethasone, etoposide, and cisplatin) every 4 wk with concurrent 5040 cGy radiation in 28 fractions for 5 wk. Patients without disease progression after CCRT were subjected to two cycles of DVIP consisted of dexamethasone, etoposide, ifosphamide, mesna, and cisplatin every 4 wk. The primary endpoint was tumor response rate, and secondary endpoints were survival and toxicities. This phase II study has been registered in the ClinicalTrials.gov (NCT00292695). Results: Thirty-three patients received CCRT, and 29 patients received two cycles of consolidation DVIP after CCRT. Among the 32 evaluable patients, 20 achieved complete response and 6 achieved partial response. The overall and complete response rate was 81% (95% CI, 68-95%) and 63% (95% CI, 46-79%), respectively. The 2-yr and 5-yr progression-free survival rate for intention-to-treat population was 64% (95% CI, 47-80%) and 60% (95% CI, 39-73%), respectively; while the corresponding overall survival rate was 73% (95% CI, 57-88%) and 66% (95% CI, 50-83%), respectively. The most common treatment-related grade 3/4 adverse event was leukopenia (85%). Conclusion: Frontline CCRT plus consolidation chemotherapy is feasible and effective for treating localized nasal NKTCL.

Original languageEnglish
Pages (from-to)130-137
Number of pages8
JournalEuropean Journal of Haematology
Volume94
Issue number2
DOIs
Publication statusPublished - 2015 Feb 1

Fingerprint

Consolidation Chemotherapy
Natural Killer T-Cells
T-Cell Lymphoma
Chemoradiotherapy
Nose
Etoposide
Dexamethasone
Cisplatin
Survival Rate
Mesna
Leukopenia
Disease-Free Survival
Disease Progression
Radiation
Safety
Survival
Therapeutics

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

Tsai, Hui Jen ; Lin, Sheng Fung ; Chen, Chu Chih ; Chen, Tsai Yun ; Su, Wu Chou ; Hwang, Wen Li ; Lin, Jin Ching ; Chiou, Tzeon Jye ; Kao, Weio Yau ; Chiu, Chang Fang ; Chang, Yi Fang ; Chang, Jeffrey S. ; Chang, Ming Chih ; Su, Ih Jen. / Long-term results of a phase II trial with frontline concurrent chemoradiotherapy followed by consolidation chemotherapy for localized nasal natural killer/T-cell lymphoma. In: European Journal of Haematology. 2015 ; Vol. 94, No. 2. pp. 130-137.
@article{c74e2ba5846d43cea504f436be7e81ce,
title = "Long-term results of a phase II trial with frontline concurrent chemoradiotherapy followed by consolidation chemotherapy for localized nasal natural killer/T-cell lymphoma",
abstract = "Purpose: A phase II trial was conducted to evaluate the therapeutic efficacy and safety profiles of frontline concurrent chemoradiotherapy (CCRT) plus consolidation chemotherapy for patients with stage I/II nasal natural killer/T-cell lymphoma (NKTCL). Patients and methods: Patients with newly diagnosed, measurable stage I/II nasal NKTCL were eligible. The CCRT included two cycles of the DEP regimen (dexamethasone, etoposide, and cisplatin) every 4 wk with concurrent 5040 cGy radiation in 28 fractions for 5 wk. Patients without disease progression after CCRT were subjected to two cycles of DVIP consisted of dexamethasone, etoposide, ifosphamide, mesna, and cisplatin every 4 wk. The primary endpoint was tumor response rate, and secondary endpoints were survival and toxicities. This phase II study has been registered in the ClinicalTrials.gov (NCT00292695). Results: Thirty-three patients received CCRT, and 29 patients received two cycles of consolidation DVIP after CCRT. Among the 32 evaluable patients, 20 achieved complete response and 6 achieved partial response. The overall and complete response rate was 81{\%} (95{\%} CI, 68-95{\%}) and 63{\%} (95{\%} CI, 46-79{\%}), respectively. The 2-yr and 5-yr progression-free survival rate for intention-to-treat population was 64{\%} (95{\%} CI, 47-80{\%}) and 60{\%} (95{\%} CI, 39-73{\%}), respectively; while the corresponding overall survival rate was 73{\%} (95{\%} CI, 57-88{\%}) and 66{\%} (95{\%} CI, 50-83{\%}), respectively. The most common treatment-related grade 3/4 adverse event was leukopenia (85{\%}). Conclusion: Frontline CCRT plus consolidation chemotherapy is feasible and effective for treating localized nasal NKTCL.",
author = "Tsai, {Hui Jen} and Lin, {Sheng Fung} and Chen, {Chu Chih} and Chen, {Tsai Yun} and Su, {Wu Chou} and Hwang, {Wen Li} and Lin, {Jin Ching} and Chiou, {Tzeon Jye} and Kao, {Weio Yau} and Chiu, {Chang Fang} and Chang, {Yi Fang} and Chang, {Jeffrey S.} and Chang, {Ming Chih} and Su, {Ih Jen}",
year = "2015",
month = "2",
day = "1",
doi = "10.1111/ejh.12405",
language = "English",
volume = "94",
pages = "130--137",
journal = "European Journal of Haematology",
issn = "0902-4441",
publisher = "Wiley-Blackwell",
number = "2",

}

Long-term results of a phase II trial with frontline concurrent chemoradiotherapy followed by consolidation chemotherapy for localized nasal natural killer/T-cell lymphoma. / Tsai, Hui Jen; Lin, Sheng Fung; Chen, Chu Chih; Chen, Tsai Yun; Su, Wu Chou; Hwang, Wen Li; Lin, Jin Ching; Chiou, Tzeon Jye; Kao, Weio Yau; Chiu, Chang Fang; Chang, Yi Fang; Chang, Jeffrey S.; Chang, Ming Chih; Su, Ih Jen.

In: European Journal of Haematology, Vol. 94, No. 2, 01.02.2015, p. 130-137.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Long-term results of a phase II trial with frontline concurrent chemoradiotherapy followed by consolidation chemotherapy for localized nasal natural killer/T-cell lymphoma

AU - Tsai, Hui Jen

AU - Lin, Sheng Fung

AU - Chen, Chu Chih

AU - Chen, Tsai Yun

AU - Su, Wu Chou

AU - Hwang, Wen Li

AU - Lin, Jin Ching

AU - Chiou, Tzeon Jye

AU - Kao, Weio Yau

AU - Chiu, Chang Fang

AU - Chang, Yi Fang

AU - Chang, Jeffrey S.

AU - Chang, Ming Chih

AU - Su, Ih Jen

PY - 2015/2/1

Y1 - 2015/2/1

N2 - Purpose: A phase II trial was conducted to evaluate the therapeutic efficacy and safety profiles of frontline concurrent chemoradiotherapy (CCRT) plus consolidation chemotherapy for patients with stage I/II nasal natural killer/T-cell lymphoma (NKTCL). Patients and methods: Patients with newly diagnosed, measurable stage I/II nasal NKTCL were eligible. The CCRT included two cycles of the DEP regimen (dexamethasone, etoposide, and cisplatin) every 4 wk with concurrent 5040 cGy radiation in 28 fractions for 5 wk. Patients without disease progression after CCRT were subjected to two cycles of DVIP consisted of dexamethasone, etoposide, ifosphamide, mesna, and cisplatin every 4 wk. The primary endpoint was tumor response rate, and secondary endpoints were survival and toxicities. This phase II study has been registered in the ClinicalTrials.gov (NCT00292695). Results: Thirty-three patients received CCRT, and 29 patients received two cycles of consolidation DVIP after CCRT. Among the 32 evaluable patients, 20 achieved complete response and 6 achieved partial response. The overall and complete response rate was 81% (95% CI, 68-95%) and 63% (95% CI, 46-79%), respectively. The 2-yr and 5-yr progression-free survival rate for intention-to-treat population was 64% (95% CI, 47-80%) and 60% (95% CI, 39-73%), respectively; while the corresponding overall survival rate was 73% (95% CI, 57-88%) and 66% (95% CI, 50-83%), respectively. The most common treatment-related grade 3/4 adverse event was leukopenia (85%). Conclusion: Frontline CCRT plus consolidation chemotherapy is feasible and effective for treating localized nasal NKTCL.

AB - Purpose: A phase II trial was conducted to evaluate the therapeutic efficacy and safety profiles of frontline concurrent chemoradiotherapy (CCRT) plus consolidation chemotherapy for patients with stage I/II nasal natural killer/T-cell lymphoma (NKTCL). Patients and methods: Patients with newly diagnosed, measurable stage I/II nasal NKTCL were eligible. The CCRT included two cycles of the DEP regimen (dexamethasone, etoposide, and cisplatin) every 4 wk with concurrent 5040 cGy radiation in 28 fractions for 5 wk. Patients without disease progression after CCRT were subjected to two cycles of DVIP consisted of dexamethasone, etoposide, ifosphamide, mesna, and cisplatin every 4 wk. The primary endpoint was tumor response rate, and secondary endpoints were survival and toxicities. This phase II study has been registered in the ClinicalTrials.gov (NCT00292695). Results: Thirty-three patients received CCRT, and 29 patients received two cycles of consolidation DVIP after CCRT. Among the 32 evaluable patients, 20 achieved complete response and 6 achieved partial response. The overall and complete response rate was 81% (95% CI, 68-95%) and 63% (95% CI, 46-79%), respectively. The 2-yr and 5-yr progression-free survival rate for intention-to-treat population was 64% (95% CI, 47-80%) and 60% (95% CI, 39-73%), respectively; while the corresponding overall survival rate was 73% (95% CI, 57-88%) and 66% (95% CI, 50-83%), respectively. The most common treatment-related grade 3/4 adverse event was leukopenia (85%). Conclusion: Frontline CCRT plus consolidation chemotherapy is feasible and effective for treating localized nasal NKTCL.

UR - http://www.scopus.com/inward/record.url?scp=84922846170&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922846170&partnerID=8YFLogxK

U2 - 10.1111/ejh.12405

DO - 10.1111/ejh.12405

M3 - Article

C2 - 24957163

AN - SCOPUS:84922846170

VL - 94

SP - 130

EP - 137

JO - European Journal of Haematology

JF - European Journal of Haematology

SN - 0902-4441

IS - 2

ER -